Summary & Overview
Local Excision and Removal of Internal Fixation Devices of Hip and Femur with CC/MCC: Inpatient Reimbursement Overview
DRG 498 addresses inpatient local excision and removal of internal fixation devices of the hip and femur with a Complication or Comorbidity or Major Complication or Comorbidity; it captures higher-acuity cases requiring additional resources. Proper coding of the procedure and any Complication or Comorbidity or Major Complication or Comorbidity is critical because Diagnosis-Related Group assignment drives Medicare inpatient reimbursement and payment variability.
DRG 498 Overview
DRG 498 covers inpatient cases involving local excision and removal of internal fixation devices of the hip and femur when accompanied by a Complication or Comorbidity or Major Complication or Comorbidity. Typical clinical scenarios include removal of plates, screws, or rods for pain, infection, nonunion, or hardware failure following prior fracture fixation. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity or Major Complication or Comorbidity elevates expected resource use and influences inpatient reimbursement classification. Accurate coding of procedures and secondary diagnoses determines assignment to this Diagnosis-Related Group and impacts payment.
Clinical Trials
- Acute surgical technique and perioperative complication reduction trials: randomized or prospective cohort studies comparing different operative approaches for removal of internal fixation devices and local excision around the hip and femur (for example, extensile exposures versus muscle-sparing approaches), or testing enhanced perioperative protocols (antibiotic prophylaxis regimens, blood management strategies, and multimodal analgesia). The studied population is adult inpatients undergoing planned or unplanned removal of plates, screws, intramedullary nails, or debriding local tissue for nonunion, hardware prominence, infection, or soft-tissue irritation; trials focus on intraoperative blood loss, operative time, and early complication rates (wound infection, fracture). This research is directly relevant to surgeons and hospital payers because it can identify techniques and perioperative bundles that lower immediate morbidity, shorten OR time and length of stay, and reduce costly readmissions or reoperations in this DRG.
- Comparative effectiveness studies of device retention versus removal strategies in complicated fracture cases: observational cohorts or pragmatic randomized studies that evaluate outcomes when hardware is removed versus retained with alternative management (for example, staged debridement with suppressive antibiotics or conversion to arthroplasty) in patients with infected, symptomatic, or failed fixation. The target population includes older adults and patients with comorbidities who present with hardware-related pain, late infection, nonunion, or implant failure; outcomes include infection eradication, need for additional surgery, functional recovery, and resource utilization over 90–365 days. Results inform clinical decision-making and utilization management by quantifying which strategies produce better long-term outcomes and lower overall cost for payers managing DRG 498 patients who often have complex, high-risk profiles.
- Post-discharge and rehabilitation outcome studies assessing functional recovery, return to mobility, and readmission risk: prospective observational studies or registry-based analyses that track gait, pain, use of home health or skilled nursing, and 30–90 day readmissions following local excision and hardware removal in hip and femur cases. These studies focus on subgroups such as frail elderly patients, those with dementia, or patients discharged to post-acute care facilities to identify predictors of delayed recovery, complications, or costly transitions of care. Findings are valuable to hospital discharge planners and payers because they help target post-acute resources, optimize rehabilitation pathways, and reduce avoidable readmissions and prolonged post-acute stays associated with this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.